Daniele Calistri

Population-based screening for hereditary breast cancer in a region of North-Central Italy.

c-kit and SCF expression in normal and tumor breast tissue.

Fecal multiple molecular tests to detect colorectal cancer in stool.

Urine telomerase: an important marker in the diagnosis of bladder cancer.

Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool.

Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.

Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT).

p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.

Relevance of urine telomerase in the diagnosis of bladder cancer.

KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression.

Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.

[Telomerase activity: a molecular marker for early diagnosis of bladder tumor].

655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.

Urine telomerase activity for the detection of bladder cancer in females.

Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.

Disease family history and modification of breast cancer risk in common BRCA2 variants.

Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer.

The current role of telomerase in the diagnosis of bladder cancer.

The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.

Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients.

Fecal DNA for noninvasive diagnosis of colorectal cancer in immunochemical fecal occult blood test-positive individuals.

Bone metastases detection by circulating biomarkers: OPG and RANK-L.

PI-PLCβ1 gene copy number alterations in breast cancer.

Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.

Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential.

EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients.

LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation.

Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.

Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.

Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.

Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue.

Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?

DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.

Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.

Assessment of DNA damage and telomerase activity in exfoliated urinary cells as sensitive and noninvasive biomarkers for early diagnosis of bladder cancer in ex-workers of a rubber tyres industry.

First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer.

Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.

Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue.

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence.

Improved stool DNA integrity method for early colorectal cancer diagnosis.

Clinical and genetic factors related to cancer-induced bone pain and bone pain relief.

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab.

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.

Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma.

Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.

miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.

Multiple primary tumors in a family with Li-Fraumeni syndrome with a TP53 germline mutation identified by next-generation sequencing.

Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.

Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors.

The potential use of urine cell free DNA as a marker for cancer.

Cell-free DNA as a diagnostic marker for cancer: current insights.

Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer.

What influences preneoplastic colorectal lesion recurrence?

Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer.

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

Stool DNA Integrity Method for Colorectal Cancer Detection.

Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma.

E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer.

Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.